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Abstract
Multiple  endocrine  neoplasia  type  1  (MEN1)  syndrome  is  a  polyglandular  autosomal
dominant  transmitted  disease  characterized  by  the  combined  occurrence  of  several
endocrine gland tumors. The main features of the syndrome include parathyroid (95%),
enteropancreatic   (40-70%),  and  anterior  pituitary  (30-40%)  tumors.  Tumors  in  MEN1
syndrome  display  a  more  aggressive  behavior  than  sporadic  tumors  and  are  more
resistant to treatment. The disease's prevalence has been estimated between 1:10'000 –
1:100'000, affecting all age groups and demonstrating a very high penetrance with clinical
and biochemical  manifestations having developed in  respectively 80 % and more than
98 % of MEN1 patients by the fifth decade. Primary hyperparathyroidism has been shown
to be the first manifestation of the syndrome amongst more than 85% of patients. MEN1,
the gene responsible for the disease, is located on chromosome 11q13. It consists of 10
exons and is translated into a 610-amino acid protein named menin that behaves as a
tumor suppressor in endocrine organs. Menin has an important role in cell division and
proliferation,  transcription,  DNA replication  and  repair,  apoptosis  and  genome stability.
More  that  450  different  mutations,  scattered  through  the  whole  sequence  and  mostly
inactivating or leading to a missing or truncated protein have been described.
We studied the MEN1 patients that were treated or followed-up at CHUV between 1995-
2015.  The objective  was  to  review and analyze  clinical  and genetic  characteristics  of
MEN1 syndrome among these patients as well as the inter- and intra-familial variability of
expression and to search for possible genotype-phenotype correlations. A large amount of
data was collected for each patient and entered into a database.  Epidemiological data
such as age ratio, mean age at first symptoms and at diagnosis, prevalence of each tumor
and proportion of patients who underwent MEN1 mutational analysis was calculated. The
data was then analyzed and compared to the literature.
21 patients  being  part  of  11  different  pedigrees  and 80% of  whom having  developed
clinical, radiological or biological signs of MEN1 at the time of the study were identified.
Among 17 out of 21 patients displaying signs or symptoms of MEN1, 82% were affected
by primary hyperparathyroidism, 76% had enteropancreatic NET, 18% pituitary tumors and
47% extended spectrum tumors, such as lipomas, carcinoids or adrenal tumors. Mutations
of the MEN1 gene were found in only four out of eleven pedigrees and consisted of two
large  deletions,  one  missense  and  one  nonsense.  Mutational  analysis  was  either  not
performed or not documented in the other pedigrees. 
Pedigree 1 being well documented, particularly interesting and displaying some unusual
features, we focused our research and analysis on it.  We report here the case of the
proband, a 40 years old patient with a metastatic pituitary carcinoma, and his family.
Several patients whose records were reviewed had benefited from a suboptimal care with
no genetic testing being made and what seemed to be an insufficient screening and follow-
up.  We recommend that MEN1 patients should be identified and gathered in  qualified
centers.  Follow-up  should  be  coordinated  by  an  endocrinologist  with  expertise  in  the
subject. 
Key words
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5
Abbreviations
CHUV: Centre Hospitalier Universitaire Vaudois
GEP: Gastroenteropancreatic
MEN 1: Multiple Endocrine Neoplasia type 1
MLPA: Multiplex Ligation-dependent Probe Amplification
NET: Neuroendocrine Tumor
NF: Non-functioning
NFPT: Non-functioning Pancreatic Tumor
PHPT: Primary Hyperparathyroidism
PP: Pancreatic Polypeptide
PPoma: PP-secreting adenoma
QMPSF: Quantitative Multiplex PCR of Short Fluorescent fragments
VIP: Vasoactive Intestinal Peptide
VIPoma: VIP-secreting adenoma
y/o: years old
ZES: Zollinger-Ellison Syndrome
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Background
Multiple endocrine neoplasia type 1 (MEN1) syndrome, also called Wermer's syndrome
(2), is a polyglandular genetic disease that is characterized by the combined occurrence of
several  endocrine  gland  tumors  (1).  The  main  features  include  parathyroid  (95%),
enteropancreatic  (40-70%), and anterior pituitary (30-40%) tumors (1,4). Enteropancreatic
tumors include gastrinomas, insulinomas, non-functioning adenomas and PPomas, as well
as  glucagonomas  and  VIPomas.  Pituitary  adenomas  are  mainly  prolactinomas,  but
somatotropinomas, corticotropinomas and non-functioning adenomas can also be found
(1).  Patients  may  also  less  frequently  present  with  adrenal  cortical  tumors,  thymic,
bronchopulmonary or gastric and duodenal carcinoids, skin tumors (facial angiofibromas,
collagenomas,  lipomas),  meningiomas  and  rarely  pheochromocytomas  (1).  Clinical
manifestations of MEN1 syndrome are related to the location of the neoplasm, its size and
its products of secretion (2). 
The prevalence of the disease has been estimated between 1:10'000 – 1:100'000, with
possible geographical clustering due to founder effect (1,5,6). The disease can affect all
age  groups  and  demonstrates  a  high  penetrance  with  clinical  and  biochemical
manifestations  having  developed  in  respectively  80 % and  more  than  98 % of  MEN1
patients by the fifth decade (1–3). However, first symptoms have been reported in patients
as young as age 5 (2). Primary hyperparathyroidism caused by parathyroid tumors has
been shown to be the first manifestation of the syndrome in more than 85% of patients,
whereas insulinomas and prolactinomas account for the remaining 15% (2).
MEN1 can either be inherited as an autosomal dominant disease, which has important
implications for family members of MEN1 patients, or occur sporadically (2,4). 
It  is  well  known that  MEN1-associated tumors have a different behavior than sporadic
tumors in non-MEN1 patients, which can be due to inherited germline mutation in all cells
(7). They are, with the exception of pituitary tumors, usually multiple and their locations
may  vary  from  the  expected  locations  for  sporadic  tumors.  Additionally,  they  usually
develop earlier  than sporadic tumors,  and can be larger and more aggressive (1,2,7).
Studies have also proven that the prevalence of metastases, especially occult metastatic
disease,  is  higher  in  MEN1 patients  than  in  patients  with  sporadic  endocrine  tumors.
MEN1-associated tumors are also more resistant to treatment (1). MEN1 patients thus
have both a reduced quality of life and life expectancy (6). The mortality associated with
tumors of the MEN1 spectrum is mostly due to enteropancreatic malignancies, particularly
non-functioning  pancreatic  NET  that  are  correlated  with  a  worse  prognosis  than
gastrinomas and insulinomas (1,3,8), but also to thymic NETs (9).
MEN1, the gene responsible for the disease, has been mapped to chromosome 11q13 by
linkage analysis (5). This gene consists of 10 exons, 9 of which translated into a 610-
amino  acid  ubiquitously  expressed  protein  named menin  (2,10).  Figure  1A displays  a
schematic  representation of  the  gene.  Menin,  a  predominantly nuclear  protein  in  non-
dividing  cells,  behaves  as  a  tumor  suppressor  and  negative  regulation  factor  or
proliferation in endocrine organs (2,11,12). Functioning as an adapter protein, it plays an
important role in cell division and proliferation, transcription, DNA replication and repair,
apoptosis  and  genome  stability,  interacting  with  numerous  transcriptions  factors,
cytoskeletal  proteins  and  cytoplasmic  cell  signaling  mediators  (6,11,12).  For  instance,
menin has been show to inhibit JunD-activated transcription, and it has been proposed
that JunD switches to an oncongen upon menin inactivation (5,7). Furthermore, knockout
7
MEN1 -/- mice showing important developmental delays and embryogenic abnormalities
demonstrate the important role of MEN1 in the embryonic development of several organs
(12).
More than a 450 different mutations of MEN1 have been described since the identification
of the gene in 1997 (2,12). The fact that these mutations are scattered through the whole
sequence  of  the  gene,  coding  regions  and  splice  sites  (2,6,12)  and  that  most  of  the
mutations are inactivating or lead to a missing or truncated protein is consistent with the
tumor suppressor gene role of MEN1 and the Knudson's two hits hypothesis (1,2,5,10,12).
The first hit is a heterozygous germline mutation either inherited from a parent in familial
cases, or acquired in early embryonic stage in sporadic cases and thus affects numerous if
not all cells at birth (13). It  occurs typically as a single-base DNA change, whereas large
chromosomal  rearrangements  or  deletions  leading  to  loss  of  heterozygosity  are  more
frequent for the second hit, however any of the mutational mechanisms can be involved
(5,12,14,15). Finally, most of the MEN1 tumors as well as many sporadic tumors harboring
a MEN1 mutation demonstrate a loss of heterozygosity at locus 11q13 (14,16). However,
the precise mechanism leading to MEN1 in the absence of a correctly functioning menin
remains to be clarified (6).
We studied MEN1 patients that were treated or followed-up at CHUV between 1995-2015.
The objective was to  review and analyze clinical  and genetic  characteristics of  MEN1
syndrome  among  these  patients  as  well  as  the  inter-  and  intra-familial  variability  of
expression with the hope of identifying possible genotype-phenotype correlations. 
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Material and methods
Source
Patients were  identified  via  the  center  for  medical  archives in  CHUV. We included all
patients with a diagnosis or suspicion of MEN1 syndrome attested by a specialist (i.e. an
endocrinologist) and that had been followed at CHUV between 1995-2015. There were no
particular exclusion criteria.
Definition
MEN1 syndrome was defined as meeting at least one of the following diagnostic criteria
(1) : 
-  Clinical :  the  presence  of  ≥  2  of  the  primary  MEN1-associated  tumors  (parathyroid,
pancreas, pituitary)
- Familial : the presence of one of the primary feature of the MEN1 syndrome, plus a first
degree relative with MEN1
- Genetic : The presence of mutations in the MEN1 gene
Database
A large  amount  of  data  was  collected  for  each  patient,  including  estimated  age  of
beginning of the symptoms, age of the first biochemical abnormality (if available), age at
diagnosis,  symptoms,  screening  strategy,  radiological  and  laboratory  finding,  tumor
pattern, treatment, outcome and, if available, genetic analysis. A database gathering this
data was then created. Obtained data was then represented in family trees and several
figures and tables using LibreOffice Impress and Calc. All pedigrees were summarized in a
table.  This  study  being  retrospective,  no  new  clinical,  biochemical  or  radiological
examinations were performed. 
Statistics
Epidemiological data such as age ratio, mean age at first symptoms and at diagnosis,
prevalence of each tumor and proportion of patients who underwent  MEN1  mutational
analysis was calculated using LibreOffice Calc. 
Genetics
Genetic  analysis  was performed prior  to  this  study in  pedigrees 1,  2,  9 and 11 using
conventional  PCR sequence analysis  of  peripheral  blood DNA.  As the  probands from
pedigrees  1  and  2  initially  tested  negative,  a  second  analysis  was  performed  using
multiplex ligation-dependent  probe amplification (MLPA) in  pedigree 1  and quantitative
multiplex PCR of short fluorescent fragments (QMPSF) in pedigree 2. The MEN1 transcript
NM_130799 was used for numbering of the mutations.
Mutations  are  named  in  this  document  according  to  the  HGVS  recommendations
regarding the nomenclature of sequence variants.
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Results
Patients
Twenty-one patients from of 11 different pedigrees were identified. Among them, 43% were
women and 57% were men. 80% had developed clinical, radiological or biological signs of
MEN1 at  the  time of  the  study.  The appearance of  first  signs was identified  in  17/21
patients at the mean age of 24 years (range 7-53 years). Mean age at diagnosis was 32
years  (range  1-65  years)  for  the  whole  cohort,  41  years  (range  15-65  years)  for  the
probands (i.e. the index case from each family) and 22 years (range 1-64 years) for the
affected family members. 
Among 17/21 patients displaying  signs or  symptoms of  MEN1,  82% were  affected by
primary hyperparathyroidism, 76% had enteropancreatic NET, 18% pituitary tumors and
47% extended spectrum tumors, such as lipomas, carcinoids or adrenal tumors. 35% also
had a tumor not in the MEN1 spectrum, indicating a potentially increased overall tumor risk
in MEN1 patients. Table 1 shows the prevalence of lesions in our cohort of patients and
compares it to published data. 
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Table 2 represents the probands from pedigrees 1-11, and summarizes genetic and clinical
features of their disease. The 10 out of 21 remaining patients were included as family
members. Over those 11 pedigrees, three represented MEN1 families,  one a probable
familial  MEN1 syndrome and four probable sporadic cases. The last three cases were
inderteminate. Figure 2 shows the course of the disease over time in probands from each
pedigree. 
Mutations of the MEN1 gene were found in only four out of eleven pedigrees. Members of
pedigree 1 have a total deletion of exons 1-10, c.[1-?_1833+?del];[=], pedigree 2 a large
deletion of exons 1-6, c.[1-?_912+?del];[=] and pedigree 9 a nonsense mutation in exon
10, c.[1726A>T];[=], p.[Lys576X];[=], leading to either a truncated protein or the absence of
the  MEN1 transcript  via  nonsense  mediated  decay.  Finally,  patients  from pedigree 11
display  a  missense  mutation  in  exon  4,  c.[773C>T];[=],  p.[Ser258Leu];[=],  which  is
predicted to have a deleterious effect and has been reported in MEN1 patients by Tham et
al.  (17).  Figure 1B shows the position of the mutations on the gene. The other seven
pedigrees were composed of the proband only and mutational analysis was either not
performed or not documented. 
Documentation was rare in all pedigrees, in exception of pedigree 1. In pedigree 2, only
two  patients  were  followed  up  at  CHUV.  In  most  of  the  cases,  particularly  when  no
mutation was documented and/or there was no familial history for MEN1, the patients were
followed up on an irregular basis.
Pedigree 1 being well documented, particularly interesting and displaying some unusual
features, we focused our research and analysis on it. 
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Case report, Pedigree 1
We report the case of a male patient, born in 1975 and further referred to as “the proband”
or  “the  patient”,  and  his  family.  The  proband  has  MEN1  syndrome  with  a  history  of
recurring  invasive  pituitary  adenomas  since  age  18  and  recurring  primary
hyperparathyroidism. At age 39, he was diagnosed with a metastatic prolactin-secreting
pituitary carcinoma. 
Clinical data
The patient was initially found to have an invasive macroprolactinoma at age 18, when he
presented with bi-temporal hemianopsia, progressive loss of visual acuity and retro-ocular
pain,  without  any signs  of  pituitary failure.  Prolactin  was  3890  μg/l  (N:  12-20  μg/l  for
males), salivary and plasma testosterone were both lowered but LH and FSH were within
the normal range. MRI showed a massive expansive process (70×55×52 mm) within the
sella region, invading the optochiasmatic cistern, the sphenoid sinus and the ethmoidal
cells  along  with  the  carotid  siphons.  Bromocriptin  treatment  was  introduced  with
disappearance of the symptoms, a decrease of prolactin up to two times the upper range
limit, normalization of the sexual hormones and reduction of the mass along with cystic
transformation of most of the macroprolactinoma on a subsequent MRI, confirming the
response to the treatment. Mild hyperprolactinemia (30-130 μg/l) persisted, and the patient
developed  hypogonadotropic  hypogonadism,  presenting  with  eunuchoid  phenotype,  no
facial and thoracic body hair, and mild galactorrhea, without any sexual dysfunction. Over
the  years,  Bromocriptin  was  replaced  by  Quinagolid  then  Cabergolin  for  digestive
intolerance. 
At age 29 the pituitary adenoma was shown to recur when the patient presented with a
novel  episode of  bi-temporal  hemianopsia and a decrease of  visual  acuity,  along with
occipital cephalea. Prolactin was within normal limits, but IGF-1 and testosterone were low,
indicating  somatotropic  and  gonadotropic  axis  insufficiency.  MRI  showed  a  tissular
transformation  of  the  invasive  macroadenoma,  which  was  partially  transsphenoidally
resected. The symptoms subsequently disappeared, with the exception of a right supero-
external quadranopsy, a hypogonadotropic hypogonadism that was supplemented and a
hypocorticism  transiently  supplemented.  Histology  showed  no  signs  of  atypia  and
confirmed  the  absence  of  prolactin  secretion,  which  allowed  the  discontinuation  of
Cabergolin  treatment.  The  patient  then  benefited  from a  complementary  radiotherapy,
during which a cystic formation developed on the tumor leading to global left anopsy, and
gonadotropic,  corticotropic  and  somatotropic  axis  failure.  Emergency  craniotomy  and
optical  nerve  decompression  was  performed  with  a  favorable  postoperative  outcome,
although partial atrophy of the left optical nerve led to permanent decreased visual acuity
and temporal hemianopsy. Sequellar panhypopituitarism required supplementation of the
corticotropic, thyrotropic and gonadotropic axis. Somatotropic axis, although insufficient as
well, was not supplemented.  
The pituitary macroadenoma recurred again at age 37, with sudden left anopsy and right
temporal  hemianopsy.  Prolactin  level  were elevated (385 μg/l)  and MRI confirmed the
tumor recurrence with extension into the left optic canal and partial extension into the left
orbit.  Cabergolin  was  reintroduced  and  the  macroprolactinoma  was  resected  by
craniotomy. Total  atrophy of the left  optical  nerve led to permanent left  eye blindness.
Histology showed diffuse and strong expression of prolactin but not of any other pituitary
hormones. The treatment was completed with Gamma Knife radioneurosurgery. 
At age 39 the patient developed right temporal hemianopsy again. Brain and pituitary MRI
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showed a new progression of the tumor in the zone that had not been treated with Gamma
Knife, along with new lesions in the supraorbital dura mater of the left frontal lobe and right
gyrus rectus suspect for metastases. Lesion of the right gyrus rectus is shown on Figure
3A. Prolactin was high at 100 μg/l. The pituitary tumor was treated by Gamma Knife and
the left frontal lesion was surgically resected. Histopathology showed a pituitary carcinoma
with diffuse and strong expression of prolactin, confirming the diagnosis. Vertebral MRI
was performed and showed lesions in the right L5 roots and dural sac at level S1-S2,
which are shown on Figure 3B and C. Cerebrospinal fluid analysis showed no malignant
cells.  The  decision  was  then  made  to  treat  the  patient  with  chemotherapy  with
temozolomide and concomitant radiotherapy. 
MEN1  syndrome  was  suspected  at  age  30  when  the  patient  was  found  to  have  an
asymptomatic  hypercalcemia  with  total  calcium  raised  to  3.05  mmol/l  (N:  2.15-2.55
mmol/l),  high  calciuria  and  high  PTH  (205  pg/ml,  N  10-70).  Parathyroid  scintigraphy
highlighted a parathyroid adenoma next to the right inferior thyroid lobe. The adenoma was
resected and calcium levels stabilized. 
Mutational  analysis  of  the  MEN1 gene  was  performed,  along  with  biological  and
radiological  evaluation.  No mutations were  found and the  evaluation  revealed only an
adeno-mucinous pancreatic cyst that was not suspect of an endocrine tumor. 
At age 37 primary hyperparathyroidism recurred with both total calcium, corrected calcium
and PTH being elevated.  The patient  was  asymptomatic,  therefore  the  treatment  was
conservative.
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Mutational analysis of the MEN1 gene
A first  mutational  analysis  was  performed  in the  proband  in  2005  at  age  30,  using
conventional PCR sequence analysis of peripheral blood DNA. No mutation was detected.
In 2010, an additional analysis was performed, using multiplex ligation-dependent probe
amplification (MLPA), a method that allows the detection of large deletions across the
gene. The MLPA analysis discovered a large deletion of exons 1-10, c.[1-?_1833+?del];[=].
After having found the deletion in the proband, his family was tested as well.  His two
children (IV.6 & 7), his brother (III.2) and three of his nephews and nieces (IV.1, 2 & 4)
tested positive for the deletion. His father (II.2) initially tested negative for mutations in the
MEN1 gene. However, he had been found to have primary hyperparathyroidism with two
parathyroid adenomas and an atypical thymic carcinoid that had been resected. Given the
family  history,  the  father's  presentation  met  the  familial  diagnosis  criteria  of  MEN1
syndrome. A second blood sample was obtained and analyzed, along with a saliva sample.
Both were negative for the familial  mutation. Tissue samples from the thymic carcinoid
were then analyzed, revealing the presence of the familial deletion in the tumor cells. This
indicates somatic mosaicism and potential germline mosaicism, which would make patient
II.2  the  founder  of  the  familial  mutation.  Further  explanations  regarding  mosaicism in
patient II.2 are to be found in the discussion.
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Familial history
The full  pedigree's family tree is represented in Figure 4. Several  family members are
affected by the disease or asymptomatic carriers of the mutation. The proband's father
(II.2) was diagnosed in 2009 at age 54 with asymptomatic primary hyperparathyroidism
while  being  investigated  for  poorly  controlled  arterial  hypertension.  Parathyroid
scintigraphy revealed two parathyroid adenomas. Exploratory cervicotomy and resection of
the adenomas was performed, along with median sternotomy and thymectomy. Histology
revealed a thymic carcinoid. The proband's daughter (IV.6), was found to have lipomas in
2012  at  10  years  old,  which  were  resected.  In  2014,  she  developed  primary
hyperparathyroidism with total hypercalcemia and high PTH, but no clinical symptoms. The
proband's brother (III.2) suffered from primary hyperparathyroidism and benefited from a
parathyroidectomy. However, information regarding age of the onset and the treatment that
he underwent was not available which led to his exclusion from the study. One of the
proband's nephew (IV.2), aged 7 years old, is currently under investigations for a probable
insulinoma after several episodes of malaise, asthenia and irritability with spontaneous
recovery after glucose administration. In some of those episodes he was found to have low
blood glucose levels and non suppressed insulin levels. Both children of the proband and
three out of his five nephews and nieces carry the mutation. However, the proband's son
(IV.7), niece (IV.1) and nephew (IV.4) were healthy carriers at ages 12, 10 and 3 years old,
respectively.
Discussion
We reviewed  clinical  and  genetic  features  of  the  syndrome  in  21  patients  among 11
pedigrees. One of the pedigrees being particularly well documented and followed-up in a
specialized center as recommended by the guidelines, we chose to focus on patients from
this family. 
Clinical features of MEN1 in our cohort
Parathyroid tumors and pancreatic NETs represent most of the tumors in our cohort as
represented in Table 1, which is comparable with the literature. The higher prevalence of
insulinomas,  glucagonomas,  VIPomas  and  PPomas  might  be  due  to  the  fact  that
plurihormonal secreting tumors were considered as the sum of individual tumors, each
secreting one hormone. For instance, multiple pancreatic NETs secreting gastrin, insulin,
glucagon and PP were treated as a gastrinoma, an insulinoma, a glucagonoma and a
PPoma.  Prevalence of  non-functioning  pancreatic  tumors,  pituitary,  adrenal,  cutaneous
tumors  and  meningiomas  is  significantly  lower  than  reported  in  the  literature.  This  is
probably  due  to  the  data  and  patients  records  being  incomplete,  or  the  absence  of
screening or  detection  of  those tumors  or  their  relation to  the  syndrome.  Most  of  the
patients  with  sporadic disease were not  followed-up at  CHUV on a regular  basis  and
screening was either incomplete or fragmented between CHUV and other institutions.
The study of the different pedigrees from our cohort highlighted the important variability in
phenotypical  presentation,  age  of  onset  and  severity  of  the  disease  that  has  been
reported,  even  between  members  of  the  same  family  (2,7).  This  is  particularly  well
illustrated by the reported case of pedigree 1. We could also observe the great morbidity
and early mortality caused by the syndrome (6). For example, probands from pedigree 8
and 10 both had multiple gastrinomas. Proband from pedigree 8 developed PHPT at age
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16 and started suffering from pyrosis and diffuse abdominal pain at age 24. Gastrin levels
were more than three times above normal range and multiple gastric ulcerous lesions were
detected. Despite receiving proton-pump inhibitory treatment, he died one year later from a
hemorrhagic  shock  caused  by  an  aorto-jejunal  fistula.  The  proband  from pedigree  10
presented with recurrent nephrolithiasis with ureteral colic at age 36. Three years later, she
was diagnosed with parathyroid adenomas. At age 44, she complained from abdominal
pain and melena, and was diagnosed with multiple gastrinomas. After several interventions
for  perforated  ulcers,  she  underwent  a  total  gastrectomy which  relieved  her  from her
symptoms  for  several  years.  Over  the  years,  hepatic,  abdominal  and  pulmonary
gastrinoma metastases were discovered and she suffered from recurrent ulcers, weight
loss,  nausea,  anorexia  and  asthenia  along  with  chronic  diarrhea despite  proton-pump
inhibitory treatment, requiring multiple surgical interventions with multiple complications.
Although still alive and more than 80 years old at the time of the study, she suffered from
great morbidity and a reduced quality of life for over half of her life. 
Interestingly and as reported in Table 2, clinical, biological and histopathological features
of the syndrome sometimes differed. The proband from pedigree 5 suffered from multiple
ulcers, one of which perforated and provoked a purulent acute peritonitis, diarrhea and
steatorrhea. However, his gastrin levels were always within the normal range. Histology
following  Whipple  duodeno-pancreatectomy  showed  three  submucosal  duodenal
gastrinomas, raising the point that gastrinomas are difficult to diagnose. The proband from
pedigree 8 had elevated gastrin, PP and VIP levels with clinical manifestations of ZES and
gastrinomas.  A CT  scan  showed  both  a  pancreatic  tumor  and  thickening  of  gastric,
duodenal  and jejunal  walls.  A hemipancreatectomy along with  jejunectomy and partial
colectomy was performed, and histological analysis showed surprisingly only PPomas and
glucagonomas.  This  is  probably due to  the multiplicity and dissemination of  tumors in
MEN1, which makes comprehensive histological analysis difficult. 
Six  out  of  the  twenty-one affected members  from the  eleven families  that  we  studied
presented  with  tumors  that  are  not  part  of  the  MEN1  spectrum  as  described  in  the
literature (1,2). Those were a benign pancreatic adenomucinous cyst (proband, pedigree
1), one mildly differentiated, partially keratinizing epidermoid carcinoma of the esophagus
(proband,  pedigree  4),  one  jejunal  leiomyoma  (pedigree  5),  one  thoracic  wall  elasto-
fibroma  (proband,  pedigree  6),  uterine  fibromyomatosis  (pedigree  9)  and  one  uterine
leiomyosarcoma with local recurrence and pulmonary metastases (proband, pedigree 11).
This might indicate that MEN1 mutations lead to an increased overall tumor risk, with wider
manifestations of tumoral disease than MEN1 syndrome. A study reported leiomyomata of
the esophagus and uterus that developed through inactivation of the MEN1 gene. Advice
was given that such tumors should be considered as MEN1 features when multiple, while
MEN1 did not seem to be involved in sporadic leiomyomas (18). This however appears not
to be universally accepted, since it was not mentioned in recent guidelines and reviews
articles (1,2). We searched the literature for reports of leiomyosarcoma in MEN1 patients,
but none were found. Further studies of MEN1 patients with aggressive tumors that are not
part of the disease spectrum are necessary to determine if MEN1 mutations are involved
in their pathogenesis. Given the multiple and not yet fully understood roles of menin in
transcription and cell  division and proliferation amongst  others (11,12) and its  multiple
partners, the possibility of an increased risk of tumors in MEN1 can not be ruled out. 
17
Genetic features
The causative gene for MEN1 was identified in 1997 and hence allowed genetic diagnostic
for  the disease.  Amongst our  cohort,  only four out  of  eleven pedigrees had a genetic
analysis with a documented mutation. Those pedigrees encompassed 66% (n=14/21) of
the patients. Among those four reported mutations, one was missense (25%), one was
nonsense (25%) and the remaining two were large deletions (50%), which were initially not
detected  and  required  further  analysis  with  Multiplex  Ligand-dependent  Probe
Amplification (MLPA) technology to be identified. According to Lemos and Thakker, large
deletions involving at least one exon account for 1% of mutations (12) and for a small part
only of the patients with clinical MEN1 in whom no mutations can be identified with non
quantitative analysis. Those large deletions require MLPA or an analogous technology to
be  detected  (12).  It  is  interesting  to  note  that  two  out  of  the  four  mutations  that  we
identified were large deletions, although this is biased by the fact that one third of the
patients in our cohort did not undergo mutational analysis. However, in our small study this
finding is not statistically significant. 
The fact that several families were not screened for MEN1 mutations has impact on their
clinical  care. Genetic counseling should be offered to every patient meeting diagnostic
criteria  of  MEN1 (suspected  or  confirmed)  and  to  family  members  of  MEN1 patients.
Indeed, genetic testing allows the confirmation of the clinical diagnosis, identifies family
members harboring the mutation and thus provides the opportunity to begin screening
early for MEN1 symptoms and manifestations. Finally, it allows to identify family members
who do not carry the mutation and therefore should not be subjected to the additional
burden of screening (1). 
Genetic mosaicism
Although MEN1 is thought to display a pure Mendelian inheritance pattern, mosaicism
occurs. As reported above, patient II.2 from pedigree 1 has been determined to be the
founder, as he was mosaic for the familial  mutation.  It  is known that variable  de novo
mutations, such as aneuploidies, large chromosomal rearrangements, insertions, deletions
or point mutations may arise at anytime during development, due to errors in chromosome
segregation or DNA replication (19–21). Generation of genetically distinct cell populations
from a single common ancestor requires such mutational event to occur postzygotic (22).
The time at which they occur is important to determine the amount of cells that will  be
affected by the mutation. Research on genetic mosaics strongly indicates that the germ
line  and  soma  diverge  early  in  development,  at  approximately  15  divisions,  and  that
multiple cells in the embryo give birth to the germ line, as shown by simultaneous somatic
and germ line mosaicism (19,21). Should a postzygotic de novo mutation occur in an exon
of a protein-coding gene, and given that the mutation is not deleterious at the cellular level,
it can lead to a genetic disorder that will have clinical manifestations. Such mutations occur
randomly  and  therefore  manifest  as  sporadic  disease  in  individuals  with  unaffected
parents. The proportion of cells that bear the mutation in each tissue depends on when
and where the mutation occurred, and the severity of the phenotype is possibly linked to
the degree of mosaicism (19,22,23). Mosaic forms of mutations leading to an autosomal
dominant disorder are a major class of mosaic mutations. In such disorder, the mutation is
usually transmitted constitutionally through the germ line to the descendance and are thus
compatible with viability (22). Mosaicism is also suspected to contribute to cancer genetics
(24). 
Although reports about mosaicism in MEN1 are rare, combined somatic and germ line
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mosaicism, also called gonosomal mosaicism (22), has been shown or suspected to play a
role in numerous genetic disorders, including McCune-Albright syndrome, osteogenesis
imperfecta, Duchenne muscular dystrophy, haemophilia, neurofibromatosis and numerous
other  neurodevelopmental  and  neuropsychiatric  disorders  (19,20).  Several  research
groups have tested the parents of apparently  de novo affected children for the mutation
causing their disease, and found some of them to have the mutation in a mosaic state. In a
study of children affected by Dravet syndrome, an epileptic encephalopathy, parents with a
high level of mosaicism were found to have presented with seizures. The clinical status of
the mosaic parent was thus related to the amount of mutation in their blood. Unrecognized
mosaicism for mutations causing several  genetic disorders could even partially explain
their variable expressivity and incomplete penetrance (24,25). Other studies showed that
some pathogenic alleles are found exclusively in the mosaic state,  being lethal  at  the
constitutional state (24). Germ line mosaicism can also be suspected when apparently
healthy parents have several children affected by the same sporadic disease (25). 
In patient II.2,  the mutation occurred postzygotic as it  could not be found in his blood
leukocyte's DNA and is therefore not present in all his cells, although genome analysis
only reflects the average genome of the examined cells (20). Having developed the MEN1-
associated tumors himself and transmitted the mutation to his descendants, the mutated
cell was probably ancestral to both somatic and germ line cells. In most of the cases, the
mosaic parent does not develop the disease and mosaicism may be hard to identify (19).
Nevertheless, MEN1 having a very high penetrance, the patient developed tumors. It has
been  reported  that  in  some  diseases,  a  mosaic  form  can  result  in  a  less  severe
presentation than a germinal form (23). Although patient II.2 was found to have PHPT with
parathyroid adenomas and a thymic carcinoid, this discovery was made at age 54 which is
significantly older than the age at which his son (the proband) was diagnosed, although
age of onset of the first biochemical alterations is not known. As ascertained by Frank, « It
seems almost certain that, for cancer, the frequency of cells that carry a somatic mutation
will strongly influence the age of onset » (26). Besides, the diagnose was an incidental
discovery as patient II.2 did not show any symptoms of MEN1 syndrome at the time. This
might reflect a milder variant of the syndrome due to mosaicism, or manifestation of the
well-known  variability  of  penetrance  and  expression.  As  observed  by  Biesecker  and
Spinner, « Mosaic disorders pose a new challenge for genotype-phenotype correlations
and  prediction  of  disease  manifestations  and  severity »  (22).  The  advent  of  new
generation screening will allow to more easily detect and diagnose mosaicism in MEN1
syndrome. 
Unusual features of the syndrome in pedigree 1
As reported above, the proband (patient III.6) and his family display several unusual and
interesting characteristics of MEN1 syndrome besides mosaicism. First, pituitary disease is
the presenting feature of the syndrome in only about  17% of cases, which leads to a
significantly longer delay to diagnose MEN1. This was the case in patient III.6 who was
diagnosed 11 years after his first symptoms. This might be explained by the younger age
at which patients may present with sporadic pituitary adenoma compared to parathyroid
adenoma or enteropancreatic tumor, leading to a less frequent consideration of the MEN1
diagnosis  in  patients  presenting with  pituitary disease (27).  Furthermore,  patient  III.6's
pituitary  tumors  displayed  an  aggressive  behavior  and  a  tendency  to  recur.  Pituitary
adenomas are known to be larger in size and more often invasive in MEN1 patients than in
sporadic  cases.  They  demonstrate  a  greater  resistance  to  treatment  and  a  lesser
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sensitivity to dopamine agonist therapy of prolactinomas has been well described (27–29).
Studies  showed  that,  compared  to  the  general  population,  patients  harboring  MEN1
mutations  tend  to  have  more  macroadenomas  and  to  be  younger  at  diagnosis,  the
youngest MEN1 patient with macroprolactinoma having been reported at age 5 (30). They
also tend to have more multi-hormonal secreting adenomas than patients with sporadic
pituitary disease (28).  Despite this,  aggressive pituitary tumors or pituitary carcinomas,
defined by craniospinal or systemic metastatic spread of the primitive tumor, are extremely
rare as they account for only 0.1% of pituitary tumors (31). No evidence has been found so
far to support a higher risk of pituitary carcinoma in MEN1 patients compared with the
general population (32). Nevertheless, abnormalities of chromosome 11 are suspected to
play a role in the aggressiveness of pituitary lesions as, according to Mete et al., “Loss of
chromosome 11p and/or 11q, the region known to harbor the MEN1 locus, could be a
critical step in prolactinoma progression to aggressive behavior” (32,33). 
Only  about  150  cases  of  pituitary  carcinoma  have  been  reported  in  the  literature.
Diagnosis of such carcinomas is difficult,  with metastatic spread being the only criteria
differentiating them from adenomas. Hence, their diagnostic is typically delayed from 7-10
years (31). Once these tumors metastatize, their prognosis is poor (34,35). In patient III.6,
the diagnostic was delayed by 20 years. This emphasizes the need for diagnostic clues.
Several  signs,  such  as  early  recurrence,  partial  antisecretory  efficacy  of  dopamine
agonists and tumor growth despite this treatment or radiotherapy might indicate a more
aggressive pituitary tumor. This does not, however, allow the distinction between a pituitary
carcinoma and an aggressive adenoma, although with close to 100% of antitumor efficacy
in the series described in literature for non-secreting pituitary adenomas, regrowth of the
tumor  is  highly  unusual  (36,37).  In  patient  III.6  development  of  the  tumor  during
radiotherapy occurred at age 30, along with drastic progression next to the zone treated by
Gamma Knife.
We searched the literature and found 3 cases of pituitary carcinomas that had been linked
to MEN1. Scheithauer et al. reported the case of a thyrotropin cell carcinoma consisting
solely of  thyrotroph cells and secreting thyrotropin,  α-subunit  and prolactin in a MEN1
patient  who  developed  both  craniospinal  and  systemic  metastases  (35).  Their  finding
spoke against an adenoma-carcinoma sequence for the development of the tumor, rather
indicating a de novo pituitary carcinoma development (35). A case of a MEN1 patient with
prolactin-secreting  pituitary  carcinoma  initially  presenting  with  pituitary  apoplexia  and
harboring  a  heterozygous  missense  mutation  in  exon  3  (p.C165R)  was  reported  by
Philippon et  al.  The patient  had received surgery,  radiotherapy and dopamine agonist
treatment that  allowed control  of  the pituitary tumor.  When the metastatic  spread was
detected, the patient responded to temozolomide chemotherapy and his tumor was still
controlled  long-term after  temozolomide withdrawal  (36).  Finally,  another  case of  non-
secreting pituitary carcinoma responding to temozolomide treatment in a MEN1 patient
was described by Morokuma et al. (38). 
The  mutation  in  this  family  may  represent  a  possible  explanation  for  these  unusual
features, although correlation between genotype and tumor aggressiveness has not been
determined (7). Large deletions have rarely been reported and account for approximately
1% of MEN1 germline mutations (39,40). However, several reports have been published
regarding a possible correlation between mutation type and phenotype, but have failed to
point  out  an  association  between  large  deletions  and  a  more  aggressive  phenotype
(17,39,41). In a report of 200 unrelated cases from Sweden that included patients with
large germline deletions, no correlation was found between mutation type and the severity
of  the  disease  (17).  Furthermore,  they  pointed  out  the  considerable  variability  of
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expression  within  families  (17).  Moreover,  mutations  of  the  MEN1  gene  are  usually
scattered throughout the whole gene and do not perturb the interaction with one particular
partner  of  menin  (17,42).  The hypothesis  proposed to  explain  this  was that  all  menin
mutations might result in a rapid degradation of the truncated protein via the ubiquitin-
proteasome pathway (17,43). 
Nevertheless, the limits of the deletion found in pedigree 1 are not known. MLPA showed a
total  deletion of all  10 exons of the gene, but the boundaries were not delimited. The
deletion may thus affect one or numerous other genes or gene promoters, which could
account for the aggressiveness of some of the tumors expressed in the family, particularly
the pituitary carcinoma. Raef et al. recently studied a large MEN1 family who displayed an
aggressive phenotype with malignant pancreatic endocrine tumors being present in five
subjects. MLPA and aCGH gene copy number analysis showed a large deletion including
the MEN1 promoter and the two first exons of the gene. LOH analysis showed somatic
deletion of  maternal  chromosome 11 that  included MEN1 locus and imprinting control
regions  located  at  11p15.  The  consequences  were  up-regulation  of  the  paternally
expressed  IGF-2 and loss of maternally expressed  CDKN1C/p57KIP2 in the pancreatic
tumors. They concluded that disruption of other genes, such as CDKN1/p57KIP2 and IGF-
2 in this case, might play a role in tumor progression and aggressive phenotype (39). We
searched the literature for reports of MEN1 patients with a large deletion of the  MEN1
gene  and  at  least  one  of  the  adjacent  genes  on  chromosome  11,  MAP4K2 and
CDC42BPG  (Figure  1C),  also  named  KAPPA-200.  We found  a  single  report  about  a
Japanese family  with  a  68kbp deletion  flanked by a  3-base pair  repeat  that  included
MEN1,  MAP4K2 and  KAPPA-200 genes  (44).  Although  having  a  large  deletion  that
included two other genes, members of the family presented with a typical MEN1 syndrome
and did not demonstrate unusually aggressive clinical features, leading Kikuchi et al. to
assume that heterozygous deletion of those genes does not cause obvious pathological
effect (44). However, further genetic analysis aiming to map the boundaries of the deletion
should be done in  pedigree 1 members,  as other  genes or  imprinting control  regions
further away on the chromosome might be affected. 
We found other studies that had searched for an additional role of other genes in patients
displaying  unusual  features  of  MEN1 syndrome.  In  a  report  about  a  patient  that  had
presented  with  a  mammosomatotroph  pituitary  adenoma  at  age  5  years,  the  role  of
somatic point mutations in the  GNAS1 gene has been questioned. No such mutations
were found, but different changes in  GNAS1 or changes in other genes have not been
excluded (30). Other genes such as GNAS1 have already been shown to play a role in the
etiology of sporadic endocrine tumors (12) and may influence development of tumors in
MEN1 syndrome as well. Similarly, the role of environmental and epigenetic factors has
been  proposed  as  menin,  functioning  as  a  scaffold  protein,  might  modulate  gene
expression  via  histone  methylation  or  acetylation.  Thus,  menin  might  both  repress  or
activate  transcription  (2,7,45),  which  would  influence  the  clinical  expression  of  the
syndrome. 
The aggressiveness of pituitary tumors in the proband contrasts with the indolence of his
parathyroid adenomas, being asymptomatic albeit recurring. Besides patient III.6, patients
IV.2 and IV.6 demonstrated early expression of the syndrome with a probable insulinoma
at age 7 years and averred PHPT at age 11 years, respectively.  However, even if  the
penetrance at  age  <10 years  is  estimated to  be 7%,  such tumors have already been
reported  in  younger  patients  (2).  Indeed,  guidelines  regarding  screening  of  mutation
carriers recommend to begin screening for insulinomas and PHPT at ages 5 years and 8
years, respectively (1). Patient IV.6 was also found to have multiple lipomas at age 10
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years, but we did not find data regarding age-related penetrance of those lesions in MEN1
patients.  Patient  II.2  was  found  with  atypical  thymic  carcinoid  and  PHPT due  to  two
parathyroid adenomas. This type of tumor is rather infrequent, with a reported prevalence
of 2% (2). As shown by Goudet et al., thymic NETs increase the risk of death by almost
four times compared to patients without those lesions (8). In comparison, gastrinomas and
non-functioning pancreatic tumors only multiply the risk of death by a factor 1.9 and 3.4,
respectively (8).  Despite  certain  family members  demonstrating  early onset  of  tumors,
III.6's  pituitary  carcinoma stands  out.  Interestingly,  none  of  the  other  family  members
displayed  a  pituitary  tumor.  If  a  factor  besides  the  MEN1  deletion  influences  the
phenotype, it might be implicated solely in pathogenesis of pituitary tumors. 
Genotype – phenotype correlation
Numerous papers investigating a potential genotype-phenotype correlation in MEN1 have
been published, although no correlations have been found. For instance, multiple studies
have been conducted on a multicenter cohort based in France and Belgium. No significant
differences regarding prevalence, histology and secretion pattern of pituitary lesions have
been found between patients  with  different  mutation types (27,28).  A case-report  of  a
patient  that  had presented with  insulinoma at age 8 years and his family also speaks
against a correlation between the mutation and clinical presentation. Although sharing the
same  mutation,  the  patient,  his  father,  and  his  three  brothers  (two  of  them  being
monozygotic  twins),  all  showed  different  disease  patterns  (46)  which  illustrates  well
phenotypic  variability.  Other  studies  report  monozygotic  twins  with  the  same  MEN1
mutation and different phenotypes (6,47) or unrelated families sharing the same mutation
and expressing  large inter-  and intra-familial  variability  (4).  It  has  been  assumed that
random chance for the second mutation might account for this phenotype variability (48).
Alternatively,  mosaicism,  allele-specific  expression,  modifier  genes  and  epigenetic  or
environmental effects may play a role regarding the poor genotype-phenotype correlations.
Nevertheless,  several  elements  challenge  these  conclusions  and  remain  incompletely
explained. First, several variants of MEN1 have been reported in patients carrying MEN1
mutations. Familial isolated hyperparathyroidism (FIHP) defined by the sole occurrence of
parathyroid  tumors  has  been  diagnosed  in  patients  with  MEN1 mutations,  with  a
predominance of missense mutations.  However,  those mutations are not clustered but
rather spread through the whole gene as in MEN1 and the some mutations have been
shown to occur both in MEN1 and FIHP, as a 4bp deletion at codons 83-84 for example
(1,2,12).  Moreover,  a  so-called  Burin  or  prolactinoma  variant  of  MEN1 with  frequent
prolactinoma (40 vs. 22% prevalence) and rare gastrinoma (10 vs 42% prevalence) has
been  reported  in  a  large  kindred  and  two  further  families  with  no  shared  mutations,
although they were found to harbor nonsense mutations (Tyr312X, Arg460X) (1,49,50).
Finally,  although  recently  confirming  the  absence  of  direct  genotype-phenotype
correlations, a multicenter study on over 800 patients conducted in France and Belgium
reported a higher risk of death due to MEN1 tumors in patients with mutations affecting the
JunD interacting domain (51). As our understanding of menin and the different pathways in
which  it  is  involved  expands,  explanations  to  these  phenomenons  and  genotype-
phenotype connections, if not correlations, may be discovered. 
Limitations
Several limitations may affect our study. First, most of the files lacked documentation and
complete  information  about  the  patient,  including  the  treatment  and the  course of  the
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disease. For example, the lack of information or documentation regarding certain patients
prevented us from determining whether the syndrome was familial or sporadic in three out
of eleven pedigrees. Additionally, most of the patients have a long history of disease. A
comprehensive and precise collection of the data is therefore difficult, particularly when
patients are followed by several centers and general practitioners. Furthermore, gathering
of different family members affected by MEN1 is sometimes difficult or impossible. Such
situations may lead to  incomplete patient  records,  adding a  new bias  to  retrospective
studies based on those files. To minimize this, we had to exclude one patient for whom we
could  not  gather  enough  information.  Moreover,  screening  guidelines  and  diagnostic
criteria as well as genetic testing availability and methods have evolved over the years,
which has likely influenced the diagnosis of certain lesions, their treatment or the outcome
in  different  patients.  Besides,  a  bias  regarding  the  age  of  patients  related  with  the
increasing  penetrance of  the syndrome with  the  age exists.  Hence,  the tumor  pattern
depends on the age. To minimize this bias, we excluded the asymptomatic patients from
our statistics regarding prevalence of the different lesions. Finally and as stated before,
seven out of eleven families did not underwent genetic testing and the MEN1 diagnosis in
these families is based solely on the clinical criteria. An effort is being made to gather DNA
for the patients that were not tested.  
Conclusion
Follow-up in  Multiple  Endocrine Neoplasia  type 1 is  challenging,  as it  requires regular
blood tests and imaging to detect the evolution of the disease and the occurrence of new
lesions. Such intensive care can be exhausting for the patients, particularly when they are
suffering from multiple and recurring tumors. Moreover, such follow-up is also demanding
for  physicians,  as  it  requires  coordination  between  the  multiple  medical  specialties
involved. According to the latest guidelines (1), such follow-up should be done in a center
with  expertise  in  MEN1  management  and  experienced  endocrinologists,  endocrine
surgeons, radiologists and geneticists. Such an organization would improve the chances of
an exhaustive,  up to  date and high-quality follow-up and screening.  Said screening is
particularly important in the context of familial syndrome, as it can greatly influence the age
at diagnosis and early treatment of tumors in order to minimize the repercussions of the
disease. 
As mentioned before, genetic counseling and testing is important for the patient's care.
Genetic testing of patients not only confirms the clinical diagnosis, but also has important
implications for the entire family. Indeed, it enables the possibility to determine whether
descendants are affected by the disease or not and thus helps establishing an efficient
screening program for patients, as well as reassuring non affected family members and
alleviating them from the burden of the screening (1).
Several  patients  whose  records  were  reviewed  experienced  suboptimal  care  with  no
genetic  testing  and  what  seemed  to  be  an  insufficient  screening  and  follow-up.  As
mentioned previously, genetic analysis of the MEN1 gene is critical for the care of MEN1
patients, especially when family members are suspected to be affected. 
We recommend that MEN1 patients should be identified and gathered in qualified centers
and that a multicenter database should be constituted. Such organization would provide a
global view of the patient's care and reveal itself useful for further studies on Swiss MEN1
patients.
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